On March 6, 2017 Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, reported that it has initiated a multi-center Phase 1 clinical trial of DCC-3014, a highly-selective small molecule CSF1R inhibitor, in patients with advanced malignancies (Press release, Deciphera Pharmaceuticals, MAR 6, 2017, View Source [SID1234518029]). Schedule your 30 min Free 1stOncology Demo! "We are excited to initiate this first-in-human Phase 1 clinical trial of DCC-3014, our small molecule switch control inhibitor of CSF1R," said Michael D. Taylor, Ph.D., Deciphera’s President and Chief Executive Officer. "Preclinical data from a number of cancer models have demonstrated that DCC-3014 has potent macrophage checkpoint inhibitory activity. We believe DCC-3014 has great potential as a novel immunomodulatory agent and an important new therapy for cancer patients."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Phase 1 clinical trial is designed to evaluate the safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of DCC-3014. Up to 55 patients with advanced malignancies will be enrolled across both dose-escalation and expansion phases of the study. For more information about the clinical trial design please visit www.clinicaltrials.gov.
"DCC-3014 inhibits tumor associated macrophages which are believed to play a key role in the tumor microenvironment," said Oliver Rosen, M.D., Chief Medical Officer at Deciphera. "By blocking macrophage immune checkpoints, DCC-3014 has demonstrated additive or synergistic immunomodulatory activity in combination with PD-1 inhibition in multiple preclinical models."
About DCC-3014
DCC-3014 was purposefully designed using the company’s proprietary Switch Control Inhibitor platform to be a highly-specific macrophage immunomodulatory agent. In preclinical models, DCC-3014 has demonstrated potent inhibition of the colony stimulating factor 1 receptor (CSF1R), an important target for the treatment of many cancer indications. Deciphera reported preclinical data demonstrating potent macrophage checkpoint inhibition with DCC-3014 in multiple cancer models both as a single agent and in combination with a PD1 inhibitor at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in April 2016. DCC-3014 is currently in Phase 1 clinical development in patients with advanced malignancies.